Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | KAT7 | O95251 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870922 | 0.80 | ACKR3 (0.58) | ACKR3HTR6BCHEKDM1AKDM4E | |
| SCHEMBL13875252 | 0.80 | ACKR3 (0.58) | ACKR3HTR6BCHEKDM1AKDM4E | |
| SCHEMBL5870792 | 0.77 | ACKR3 (0.67) | ACKR3HTR6BCHEKDM1AKDM4E | |
| SCHEMBL5871116 | 0.77 | ACKR3 (0.67) | ACKR3HTR6BCHEKDM1AKDM4E | |
| SCHEMBL6286686 | 0.77 | FEN1 (0.47) | ACKR3ALDH1A1LMNAHTR6BCHE | |
| SCHEMBL13875251 | 0.77 | ACKR3 (0.54) | ACKR3HTR6BCHEKDM1AMEN1 | |
| SCHEMBL6714776 | 0.77 | ACKR3 (0.57) | ACKR3HTR6BCHEKDM1AKDM4E | |
| SCHEMBL21664407 | 0.76 | TGFBR1 (0.62) | ACKR3ALDH1A1LMNAHTR6BCHE | |
| SCHEMBL3985931 | 0.74 | METAP2 (0.70) | — | |
| SCHEMBL27158621 | 0.73 | KAT7 (0.56) | ACKR3HTR6BCHEKDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872716-B2 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | WU XINHE (US) | 2004-11-25 | — | — | US | disclosed |
| US-6703383-B2 | HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002022579-A2 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | TRPV1, CNR2, TRPM5 | ACKR3 1123/4885ALDH1A1 1473/4885LMNA 4455/4885 |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | TRPV1, CNR2, TRPM5 | ACKR3 1123/4885ALDH1A1 1473/4885LMNA 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.